GlassScriptPhysician profile
Brian Scott Winfield
NPI 1295827053
$2,832.84
in general payments reported to CMS, 2019-2025
23 companies · $1,964 in 2025
The $1,964 reported for 2025 was more than what 96% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $869 · 2025: $1,964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,832.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $604.54 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Phathom Pharmaceuticals, INC. | $291.95 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $243.09 | 2024-2025 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $208.76 | 2024-2025 | Tremfya, Simponi, Stelara |
| Ardelyx, INC. | $194.99 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $185.75 | 2024-2025 | Omvoh |
| Genzyme Corporation | $148.83 | 2025 | |
| Madrigal Pharmaceuticals | $137.13 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $117.41 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $102.07 | 2024-2025 | Iqirvo, Bylvay |
| Pfizer INC. | $91.89 | 2024-2025 | |
| Celltrion USA INC. | $87.31 | 2024 | Vegzelma |
| Celgene Corporation | $75.93 | 2024 | Zeposia |
| Daiichi Sankyo INC. | $60.25 | 2025 | Injectafer |
| Evoke Pharma, INC. | $55.15 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $49.60 | 2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $39.93 | 2024-2025 | Clenpiq, Rebyota |
| Digestive Care, INC. | $30.72 | 2025 | Pertzye |
| Mallinckrodt Hospital Products INC. | $28.94 | 2025 | Terlivaz |
| Novo Nordisk INC | $23.60 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $22.41 | 2025 | Zenpep |
| Braintree Laboratories, INC. | $17.06 | 2024 | Suflave, Sutab |
| Abbvie INC. | $15.53 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Winfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.